EYP-1901 Peak Sales Opportunity is Underappreciated - Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $31.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
